CD34 and Schnyder corneal dystrophy: The more efficient transduction of CD34+ cells in vitro and in vivo achieved with our forward-oriented globin vector (Figs. 1, 2, and 3, and Supplementary Figs. 2 and 4) should advance gene therapy for hemoglobin disorders by allowing us to achieve transduction levels required for broad success in SCD.